Oxprenolol Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Oxprenolol
Therapeutic Class: Beta-blocker
Subclass: Non-selective beta-adrenoceptor antagonist with intrinsic sympathomimetic activity (ISA)
Speciality: Cardiology
Subclass: Non-selective beta-adrenoceptor antagonist with intrinsic sympathomimetic activity (ISA)
Speciality: Cardiology
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
• Tablets: 20 mg, 40 mg, 80 mg
Route(s): Oral
Formulations Available in India:
• Tablets: 20 mg, 40 mg, 80 mg
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶ Hypertension
| Parameter | Recommendation |
|
Starting dose
|
20–40 mg twice daily |
|
Titration
|
Increase every 1–2 weeks based on blood pressure response |
|
Usual maintenance dose
|
80–160 mg/day in 2–3 divided doses |
|
Maximum dose
|
320 mg/day |
Clinical Notes:
• May be used as monotherapy or in combination with other antihypertensives
• Intrinsic sympathomimetic activity (ISA) causes less resting bradycardia compared to beta-blockers without ISA
• Caution in elderly due to risk of orthostatic hypotension
• Not a first-line agent in current Indian hypertension protocols
• May be used as monotherapy or in combination with other antihypertensives
• Intrinsic sympathomimetic activity (ISA) causes less resting bradycardia compared to beta-blockers without ISA
• Caution in elderly due to risk of orthostatic hypotension
• Not a first-line agent in current Indian hypertension protocols
▶ Angina Pectoris (Chronic Stable)
| Parameter | Recommendation |
|
Starting dose
|
20 mg twice daily |
|
Titration
|
Increase gradually based on clinical response and heart rate |
|
Usual maintenance dose
|
40–80 mg twice or thrice daily |
|
Maximum dose
|
320 mg/day |
Clinical Notes:
• Consider use in patients intolerant to cardioselective beta-blockers
• Monitor exercise tolerance and resting heart rate
• Avoid abrupt discontinuation — may precipitate angina or myocardial infarction
• Consider use in patients intolerant to cardioselective beta-blockers
• Monitor exercise tolerance and resting heart rate
• Avoid abrupt discontinuation — may precipitate angina or myocardial infarction
▶ Cardiac Arrhythmias (including supraventricular tachycardias)
| Parameter | Recommendation |
|
Starting dose
|
20–40 mg three times daily |
|
Titration
|
Adjust as needed for rate control |
|
Usual maintenance dose
|
120–240 mg/day in divided doses |
|
Maximum dose
|
320 mg/day |
Clinical Notes:
• Monitor ECG closely during initiation and titration
• Effective for rate control in atrial fibrillation and SVT
• ISA property may be advantageous in patients with borderline bradycardia
• Monitor ECG closely during initiation and titration
• Effective for rate control in atrial fibrillation and SVT
• ISA property may be advantageous in patients with borderline bradycardia
Secondary Indications — Adults (Off-label, if any)
▶ Essential Tremor — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
20 mg twice daily |
|
Titration
|
Increase based on tremor control and tolerability |
|
Usual maintenance dose
|
40–80 mg twice daily |
|
Maximum dose
|
160 mg/day |
|
Duration
|
Long-term; reassess periodically |
• Specialist only — under neurology guidance
• Evidence basis: Extrapolated from propranolol data; selected patients unresponsive to propranolol; limited direct evidence
• Evidence basis: Extrapolated from propranolol data; selected patients unresponsive to propranolol; limited direct evidence
▶ Migraine Prophylaxis — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
20 mg twice daily |
|
Titration
|
Increase to 40 mg twice daily after 2 weeks if tolerated |
|
Usual maintenance dose
|
40–80 mg twice daily |
|
Maximum dose
|
160 mg/day |
|
Duration
|
Minimum 2–3 months trial; reassess efficacy |
• Specialist only — under neurology guidance
• Evidence basis: Limited data; not first-line agent; propranolol preferred in Indian practice
• Preferred alternative: Propranolol (better evidence, NLEM-listed)
• Evidence basis: Limited data; not first-line agent; propranolol preferred in Indian practice
• Preferred alternative: Propranolol (better evidence, NLEM-listed)
▶ Anxiety Disorders (Situational/Performance Anxiety) — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
20–40 mg as needed, 30–60 minutes before anticipated anxiety-provoking situation |
|
Titration
|
Not applicable for PRN use |
|
Usual maintenance dose
|
20–40 mg PRN |
|
Maximum dose
|
80 mg/day |
• Evidence basis: Beta-blocker class effect; propranolol more commonly used; Indian psychiatry practice
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not routinely used in children — safety and efficacy not established for routine paediatric use in hypertension or arrhythmias.
Secondary Indications — Paediatric Doses (Off-label, if any)
▶ Supraventricular Tachycardia / Arrhythmias — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
0.5–1 mg/kg/day in 2–3 divided doses |
|
Titration
|
Increase gradually based on heart rate response and tolerability |
|
Usual maintenance dose
|
1–2 mg/kg/day in divided doses |
|
Maximum dose
|
4 mg/kg/day |
|
Minimum age
|
Not recommended below 12 years except under paediatric cardiologist guidance |
• Specialist only — requires paediatric cardiology supervision
• Evidence basis: Limited paediatric data; other beta-blockers (propranolol, atenolol) preferred in paediatric practice
• Evidence basis: Limited paediatric data; other beta-blockers (propranolol, atenolol) preferred in paediatric practice
Safety Monitoring:
• Continuous ECG monitoring during initiation
• Blood pressure and heart rate monitoring at each visit
• Monitor for signs of bronchospasm, fatigue, and hypoglycaemia
• Continuous ECG monitoring during initiation
• Blood pressure and heart rate monitoring at each visit
• Monitor for signs of bronchospasm, fatigue, and hypoglycaemia
Clear statement: Use in children is off-label with very limited evidence. Propranolol or atenolol are preferred alternatives in paediatric cardiology practice in India.
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| Mild to moderate impairment | No dose adjustment required |
| Severe impairment (CrCl <30 mL/min) | Use with caution; monitor heart rate and blood pressure closely |
| Haemodialysis | Limited data; minimal dialysis clearance expected; no supplemental dose required |
Note: Oxprenolol is primarily hepatically metabolised — renal impairment has minimal direct impact but may affect overall drug clearance.
HEPATIC ADJUSTMENT
| Severity | Recommendation |
| Mild impairment | No specific adjustment required; monitor heart rate and blood pressure |
| Moderate impairment | Consider dose reduction (start at lower end of dose range); slower titration |
| Severe impairment | Avoid or use only with specialist input; significant risk of accumulation due to hepatic metabolism |
CONTRAINDICATIONS
• Sinus bradycardia (<50 bpm)
• Second or third-degree atrioventricular block (without pacemaker)
• Sick sinus syndrome (without pacemaker)
• Cardiogenic shock
• Decompensated heart failure
• Severe hypotension (systolic BP <90 mmHg)
• Bronchial asthma or history of severe bronchospasm
• Severe COPD with active bronchospastic component
• Known hypersensitivity to oxprenolol or other beta-blockers
• Untreated phaeochromocytoma
• Metabolic acidosis
• Second or third-degree atrioventricular block (without pacemaker)
• Sick sinus syndrome (without pacemaker)
• Cardiogenic shock
• Decompensated heart failure
• Severe hypotension (systolic BP <90 mmHg)
• Bronchial asthma or history of severe bronchospasm
• Severe COPD with active bronchospastic component
• Known hypersensitivity to oxprenolol or other beta-blockers
• Untreated phaeochromocytoma
• Metabolic acidosis
CAUTIONS
• Diabetes mellitus — may mask hypoglycaemia symptoms (tachycardia, tremor); sweating preserved
• Mild to moderate COPD without active bronchospasm — use with caution despite ISA; non-selective beta-blockade risk remains
• Peripheral vascular disease — may worsen claudication symptoms
• Thyrotoxicosis — may mask clinical signs (tachycardia); do not withdraw abruptly after thyroid control
• First-degree AV block — use with caution
• Depression — beta-blockers may exacerbate mood disorders
• Psoriasis — may worsen or trigger psoriatic lesions
• Myasthenia gravis — may worsen muscle weakness
• History of anaphylactic reactions — may blunt response to epinephrine
• Prinzmetal (variant) angina — potential for coronary vasospasm
• Abrupt discontinuation — taper gradually over 1–2 weeks to avoid rebound tachycardia, hypertension, or angina
• Mild to moderate COPD without active bronchospasm — use with caution despite ISA; non-selective beta-blockade risk remains
• Peripheral vascular disease — may worsen claudication symptoms
• Thyrotoxicosis — may mask clinical signs (tachycardia); do not withdraw abruptly after thyroid control
• First-degree AV block — use with caution
• Depression — beta-blockers may exacerbate mood disorders
• Psoriasis — may worsen or trigger psoriatic lesions
• Myasthenia gravis — may worsen muscle weakness
• History of anaphylactic reactions — may blunt response to epinephrine
• Prinzmetal (variant) angina — potential for coronary vasospasm
• Abrupt discontinuation — taper gradually over 1–2 weeks to avoid rebound tachycardia, hypertension, or angina
PREGNANCY
| Consideration | Recommendation |
| Overall safety | Use only if clearly needed; limited human pregnancy data |
| Risk | Potential for fetal bradycardia, hypoglycaemia, intrauterine growth restriction |
| Preferred alternatives | Labetalol (hypertension in pregnancy); metoprolol (arrhythmias) — better established safety data |
| When it may be used | Only if preferred alternatives not suitable; under obstetric and specialist supervision |
| Monitoring | Fetal growth (serial ultrasound), fetal heart rate; neonatal heart rate, blood pressure, and glucose for 48–72 hours post-delivery |
LACTATION
| Consideration | Recommendation |
| Compatibility | Compatible with breastfeeding with caution |
| Drug levels in milk | Low levels expected |
| Preferred alternatives | Propranolol, labetalol, metoprolol (more breastfeeding data available) |
| Infant monitoring | Heart rate, feeding difficulties, lethargy, poor weight gain, signs of beta-blockade |
ELDERLY
| Consideration | Recommendation |
| Starting dose | 10–20 mg twice daily |
| Titration | Slower titration required — increase dose at 2–4 week intervals |
| Risks | Bradycardia, orthostatic hypotension, dizziness, falls, fatigue, confusion, cognitive effects |
| Monitoring | Blood pressure (supine and standing), heart rate, renal function, mental status |
• Increased sensitivity to beta-blockade effects due to reduced hepatic and renal reserve
• Assess fall risk before initiation
• Elderly may respond adequately to lower maintenance doses
• Assess fall risk before initiation
• Elderly may respond adequately to lower maintenance doses
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect / Mechanism | Recommendation |
| Verapamil, Diltiazem | Additive negative chronotropic and dromotropic effects; risk of severe bradycardia, AV block, heart failure |
Avoid concurrent use; avoid IV verapamil/diltiazem in patients on oxprenolol
|
| Clonidine | Risk of severe rebound hypertension if clonidine stopped abruptly |
Discontinue oxprenolol several days before stopping clonidine; taper clonidine slowly
|
| Digoxin | Additive bradycardia and AV block risk |
Monitor heart rate closely; consider digoxin dose reduction
|
| Class I antiarrhythmics (quinidine, disopyramide, flecainide) | Enhanced myocardial depression; additive negative inotropic effects |
Avoid combination or use with extreme caution
|
| MAOIs (non-selective) | May potentiate hypotensive effects |
Avoid combination
|
| Fingolimod | Additive bradycardia risk |
Avoid initiation of fingolimod in patients on oxprenolol
|
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect / Mechanism | Recommendation |
| Insulin, Sulfonylureas | Beta-blockade masks hypoglycaemia symptoms (tachycardia, tremor) | Monitor blood glucose closely; educate patient |
| NSAIDs | May attenuate antihypertensive effect via prostaglandin inhibition | Monitor blood pressure |
| Rifampicin | May reduce oxprenolol levels via CYP enzyme induction | Monitor clinical response; may need dose adjustment |
| Amiodarone | Additive bradycardia risk | Monitor heart rate and ECG |
| Tricyclic antidepressants | May increase hypotensive effect; altered beta-blocker metabolism | Monitor blood pressure |
| SSRIs (fluoxetine, paroxetine) | CYP2D6 inhibition may increase oxprenolol levels | Monitor for excessive beta-blockade |
| Anaesthetic agents | Enhanced hypotensive effect | Inform anaesthetist; do not discontinue abruptly before surgery |
| Alcohol | Additive hypotensive effects | Advise moderation |
| Ergot alkaloids | Additive vasoconstriction | Monitor for peripheral ischaemia |
COMMON ADVERSE EFFECTS
• Fatigue
• Dizziness
• Cold extremities
• Bradycardia (less common than with non-ISA beta-blockers)
• Gastrointestinal upset (nausea, diarrhoea)
• Headache
• Insomnia or vivid dreams (due to lipophilicity and CNS penetration)
• Exercise intolerance
• Weight gain
• Dizziness
• Cold extremities
• Bradycardia (less common than with non-ISA beta-blockers)
• Gastrointestinal upset (nausea, diarrhoea)
• Headache
• Insomnia or vivid dreams (due to lipophilicity and CNS penetration)
• Exercise intolerance
• Weight gain
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Note |
| Bronchospasm | Especially in patients with asthma or reactive airway disease; discontinue immediately |
| Severe bradycardia or AV block | May require atropine, temporary pacing, or discontinuation |
| Severe hypotension | Risk heightened in elderly or overdose; supportive care required |
| Worsening heart failure | Monitor closely; may require dose reduction or discontinuation |
| Rebound phenomena on abrupt withdrawal | Tachycardia, angina, myocardial infarction — always taper gradually |
| Depression, confusion, hallucinations | More common in elderly; consider dose reduction or alternative agent |
| Peripheral ischaemia | Worsening of Raynaud’s phenomenon or claudication |
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
Blood pressure (supine and standing), resting heart rate, ECG (if arrhythmia indication), renal function, hepatic function, blood glucose (in diabetics) |
|
After initiation/dose change
|
Heart rate and blood pressure at 1–2 weeks |
|
Long-term
|
Blood pressure, heart rate every 2–3 months; periodic ECG in arrhythmia patients; periodic assessment of mood and exercise tolerance |
BRANDS AVAILABLE IN INDIA
• Trasicor (Novartis — limited availability)
• Generic formulations may be available through institutional supply
• Generic formulations may be available through institutional supply
Note: Oxprenolol availability in India is limited compared to other beta-blockers. Confirm availability before prescribing.
PRICE RANGE (INR)
| Strength | Approximate Price Range (per tablet) |
| 20 mg | ₹2–₹4 (generic) |
| 40 mg | ₹5–₹8 (branded) |
| 80 mg | ₹8–₹12 (branded) |
• Not included in NLEM 2022
• Not under NPPA price control
• Limited availability in retail pharmacies; may require institutional procurement
• Not under NPPA price control
• Limited availability in retail pharmacies; may require institutional procurement
CLINICAL PEARLS
• Oxprenolol has intrinsic sympathomimetic activity (ISA) — causes less resting bradycardia compared to beta-blockers without ISA (propranolol, atenolol); may be useful in patients with borderline low heart rate
• Despite ISA, avoid in asthma/COPD — non-selective beta-blockade risk remains significant; cardioselective agents (bisoprolol, metoprolol) are safer alternatives
• Not a first-line agent for hypertension in current Indian protocols; consider in specific patients with coexisting tachyarrhythmias or intolerance to other beta-blockers
• Lipophilic agent — readily crosses blood-brain barrier; may cause CNS side effects such as vivid dreams, insomnia, or depression
• Never stop abruptly — taper over 1–2 weeks to prevent rebound tachycardia, hypertension, angina, or myocardial infarction
• Limited availability in India may necessitate alternative beta-blockers for most indications; propranolol, atenolol, metoprolol, and bisoprolol are more readily available
TAGS
oxprenolol; beta-blocker; non-selective; ISA; intrinsic sympathomimetic activity; hypertension; angina; arrhythmia; tachycardia; pregnancy-caution; elderly-caution; Schedule H
VERSION
RxIndia v1.0 — 19 Feb 2026
REFERENCES
• CDSCO
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• API Textbook of Medicine
• AIIMS Drug Formulary
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Harrison’s Principles of Internal Medicine
• NLEM 2022 (confirmation of non-inclusion)
• Indian specialist prescribing practices (for off-label indications)
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• API Textbook of Medicine
• AIIMS Drug Formulary
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Harrison’s Principles of Internal Medicine
• NLEM 2022 (confirmation of non-inclusion)
• Indian specialist prescribing practices (for off-label indications)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.